CDKL5 Deficiency Disorder Biomarker Study Approval

Ulysses Neuroscience Ltd. has obtained ethical approval for the CDKL5 biomarker study at Besta Hospital in Milan! As a company committed to advancing research on brain disorders, we are thrilled to lead this ground-breaking study. This is the first age/gender matched control biomarker study in Italy, marking a significant milestone in CDKL5 research. With the generous support of the LouLou Foundation, this study aims to uncover potential alterations in plasma proteins associated with brain disorders in patients with CDKL5 Deficiency Disorder (CDD). The findings hold the potential to pave the way for early clinical biomarkers and the development of new therapies.

If your child or someone you know is affected by CDD, you can sign up for the study or request more information by emailing Carolina De Pasquale, our Patient Insight Manager and Clinical Lead, at

Stay tuned for updates as we continue to make progress in CDKL5 research. Together, we can make a difference!